NCT04626635 2026-04-09
COMBINE-EGFR-1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
Regeneron Pharmaceuticals
M.D. Anderson Cancer Center
Biohaven Pharmaceuticals, Inc.
Intergroupe Francophone de Cancerologie Thoracique
Inimmune Corporation
Sanofi
Jules Bordet Institute